FINWIRES · TerminalLIVE
FINWIRES

調査速報:マイクロソフトが3月期決算で予想を上回り、Azureは驚異的な40%の成長を記録

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。マイクロソフト(MSFT)は、クラウドとAIの継続的な成長に牽引され、3月期決算で売上高829億ドル(前年同期比18%増、当社予想16%増)を計上しました。1株当たり利益(EPS)は4.27ドルとなり、予想の4.06ドルを上回りました。AI関連売上高は年間換算で370億ドル(前年同期比123%増)に達し、Microsoft Cloudは545億ドル(前年同期比29%増、当社予想28%増)を計上しました。Azureは40%増(当社予想38%増)となりました。前年同期比99%増の6,270億ドルという驚異的な商用RPO(リード・パー・オーダー)の急増は、収益の見通しを示すとともに、複数年契約のクラウド契約に対する企業の旺盛な需要を反映しています。当社は、同社が決算説明会でガイダンスを提供するものと予想しています。営業利益率は45.7%から46.3%に拡大し、クラウド事業の規模拡大に伴うMSFTの営業レバレッジ効果の高さを示しました。プロダクティビティ部門の売上高は350億ドル(当社の予想15%増に対し17%増)となり、パーソナルコンピューティング部門の売上高は当社の予想6%減に対しわずか1%減にとどまりました。AIの収益化とクラウド事業の力強い成長軌道、そして利益率の拡大が相まって、MSFTのエンタープライズ市場における競争力をさらに強化するものと確信しています。

Related Articles

Asia

Electro Optic Systems Reports Contract Backlog Growth as of March 31

Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.

$ASX:EOS
Asia

Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance

Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.

$ASX:REG
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.

$MDLZ